SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across i ...

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 2:00 PM ET [1] - Senti Bio's Gene Circuits are engineered to target cancer cells while sparing healthy cells, enhancing specificity, and allowing for post-administration control [3] Company Overview - Senti Bio is dedicated to creating new medicines for patients with incurable diseases through its synthetic biology platform [3] - The company's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications [3] - Preclinical studies have shown the effectiveness of Senti's Gene Circuits in both NK and T cells, with potential applications beyond oncology [3] Investor Engagement - Management will be available for in-person one-on-one meetings with qualified investors during the conference [2] - A live video webcast of the presentation will be accessible on the company's website, with a replay available for 90 days [2]